{"id":1057,"date":"2026-01-04T20:28:52","date_gmt":"2026-01-04T20:28:52","guid":{"rendered":"https:\/\/www.h2founders.com\/?p=1057"},"modified":"2026-01-04T21:39:35","modified_gmt":"2026-01-04T21:39:35","slug":"alzheimers-dementia-breakthrough-czech-patient-friendly-solution-turns-problem-into-opportunity-and-investors-dont-want-to-miss-out","status":"publish","type":"post","link":"https:\/\/www.h2founders.com\/cs\/alzheimers-dementia-breakthrough-czech-patient-friendly-solution-turns-problem-into-opportunity-and-investors-dont-want-to-miss-out\/","title":{"rendered":"Alzheimerova demence: Pr\u016flomov\u00e9 \u010desk\u00e9 \u0159e\u0161en\u00ed \u0161etrn\u00e9 k pacient\u016fm m\u011bn\u00ed probl\u00e9m v p\u0159\u00edle\u017eitost. A investo\u0159i u toho necht\u011bj\u00ed chyb\u011bt."},"content":{"rendered":"

Alzheimerova demence pat\u0159\u00ed mezi nejv\u011bt\u0161\u00ed v\u00fdzvy nejen st\u00e1rnouc\u00ed spole\u010dnosti. M\u016f\u017ee zas\u00e1hnout kohokoli z n\u00e1s a kdykoli \u2013 p\u0159\u00edmo, v rodin\u011b \u010di v na\u0161em bl\u00edzk\u00e9m okol\u00ed \u2013 a v ur\u010dit\u00fdch f\u00e1z\u00edch si ji pacient u\u017e ani neuv\u011bdomuje. P\u0159in\u00e1\u0161\u00ed masivn\u00ed z\u00e1t\u011b\u017e pro rodiny, zdravotnick\u00fd syst\u00e9m i ekonomiku a z\u00e1rove\u0148 klade z\u00e1sadn\u00ed ot\u00e1zku: budeme jen ne\u010dinn\u011b p\u0159ihl\u00ed\u017eet, nebo se aktivn\u011b zapoj\u00edme do hled\u00e1n\u00ed nov\u00fdch, k pacient\u016fm \u0161etrn\u011bj\u0161\u00edch \u0159e\u0161en\u00ed?<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Pr\u00e1v\u011b v t\u00e9to oblasti p\u0159ich\u00e1z\u00ed z \u010cesk\u00e9 republiky zpr\u00e1va, kter\u00e1 m\u00e1 potenci\u00e1l um\u00edstit na\u0161i zemi na mapu sv\u011btov\u00e9 medic\u00edny. St\u00e1tn\u00ed \u00fastav pro kontrolu l\u00e9\u010div (S\u00daKL) schv\u00e1lil prvn\u00ed klinickou studii v \u010cR zam\u011b\u0159enou na hodnocen\u00ed bezpe\u010dnosti inhalace molekul\u00e1rn\u00edho vod\u00edku u pacient\u016f s m\u00edrnou kognitivn\u00ed poruchou (MCI), kter\u00e1 je \u010dast\u00fdm p\u0159edstupn\u011bm Alzheimerovy demence. Za projektem stoj\u00ed \u010desk\u00e1 spole\u010dnost H2 Medical Technologies ze skupiny H2 Global Group.<\/p>\n\n\n\n

\n

\u201eChceme p\u0159in\u00e9st kvalitn\u00ed data a otev\u0159\u00edt debatu o tom, jak molekul\u00e1rn\u00ed vod\u00edk zapad\u00e1 do medic\u00edny budoucnosti. Na\u0161e \u0159e\u0161en\u00ed p\u0159edstavuje zcela novou, neinvazivn\u00ed a bezpe\u010dnou metodu, kter\u00e1 m\u00e1 potenci\u00e1l st\u00e1t se pr\u016fkopnick\u00fdm p\u0159\u00edstupem, jeho\u017e \u00fa\u010dinky na neurodegenerativn\u00ed onemocn\u011bn\u00ed jsou nyn\u00ed p\u0159edm\u011btem klinick\u00e9ho testov\u00e1n\u00ed,\u201c \u0159\u00edk\u00e1 PharmDr. Milan Kraj\u00ed\u010dek, \u0159editel v\u00fdzkumu, v\u00fdvoje a v\u00fdroby a spoluzakladatel H2 Global Group.<\/p>\n<\/blockquote>\n\n\n\n

Pro\u010d u\u017e si nem\u016f\u017eeme dovolit \u010dekat<\/h3>\n\n\n\n

Na rozvoji Alzheimerovy choroby se pod\u00edl\u00ed kombinace r\u016fzn\u00fdch faktor\u016f: vy\u0161\u0161\u00ed v\u011bk a genetick\u00e1 dispozice, kardiovaskul\u00e1rn\u00ed rizika (vysok\u00fd krevn\u00ed tlak, cukrovka, obezita, kou\u0159en\u00ed), nezdrav\u00fd \u017eivotn\u00ed styl, nedostatek pohybu a sp\u00e1nku, dlouhodob\u00fd stres a mozkov\u00e9 procesy jako oxida\u010dn\u00ed stres a z\u00e1n\u011bty. V\u00fdsledkem nen\u00ed jen \u201ezapom\u00edn\u00e1n\u00ed\u201c, ale postupn\u00e1 ztr\u00e1ta sob\u011bsta\u010dnosti a obrovsk\u00fd tlak na rodinu a pe\u010dovatelsk\u00fd syst\u00e9m.<\/p>\n\n\n\n

\u201eZ pohledu neurologa u\u017e nejde jen o medic\u00ednsk\u00fd probl\u00e9m, ale o z\u00e1sadn\u00ed celospole\u010densk\u00e9 t\u00e9ma. Pokud ho neza\u010dneme aktivn\u011b \u0159e\u0161it dnes, \u010dek\u00e1 n\u00e1s velmi t\u011b\u017ek\u00e1 budoucnost,\u201c varuje prof. MUDr. David \u0160koloud\u00edk, Ph.D., neurolog, kter\u00fd tuto pr\u016flomovou studii povede.<\/p>\n\n\n\n

Nav\u00edc se po covidov\u00e9 krizi zved\u00e1 glob\u00e1ln\u00ed \u201etsunami popt\u00e1vky\u201c po diagnostice a p\u00e9\u010di, specializovan\u00fdch l\u016f\u017ek\u00e1ch, vy\u0161kolen\u00e9m person\u00e1lu i dom\u00e1c\u00ed a komunitn\u00ed p\u00e9\u010di. Demence se definitivn\u011b p\u0159esouv\u00e1 z okraje geriatrie do centra spole\u010densk\u00e9 a ekonomick\u00e9 debaty nadch\u00e1zej\u00edc\u00edch dek\u00e1d.<\/p>\n\n\n\n

Molekul\u00e1rn\u00ed vod\u00edk: \u010cesk\u00fd patent, sv\u011btov\u00e1 ambice<\/h3>\n\n\n\n

Molekul\u00e1rn\u00ed vod\u00edk (H\u2082) je plyn p\u0159irozen\u011b se vyskytuj\u00edc\u00ed v organismu, kter\u00fd v posledn\u00edch letech p\u0159itahuje pozornost v\u011bdc\u016f po cel\u00e9m sv\u011bt\u011b. Tis\u00edce studi\u00ed popisuj\u00ed jeho antioxida\u010dn\u00ed, protiz\u00e1n\u011btliv\u00fd a bun\u011b\u010dn\u011b ochrann\u00fd potenci\u00e1l a schopnost ovliv\u0148ovat energetick\u00fd metabolismus. Odborn\u00edci jej nevn\u00edmaj\u00ed jako \u201ez\u00e1zra\u010dn\u00fd l\u00e9k\u201c, ale jako modul\u00e1tor bun\u011b\u010dn\u00fdch proces\u016f a slibn\u00fd dopln\u011bk dal\u0161\u00edch postup\u016f p\u00e9\u010de o zdrav\u00ed.<\/p>\n\n\n\n

\u201eVn\u00edm\u00e1me molekul\u00e1rn\u00ed vod\u00edk jako n\u00e1stroj, kter\u00fd dok\u00e1\u017ee \u0161etrn\u011b ovliv\u0148ovat bun\u011b\u010dn\u00e9 procesy. Pr\u00e1v\u011b proto pot\u0159ebujeme dal\u0161\u00ed kvalitn\u00ed klinick\u00e1 data, abychom p\u0159esn\u011b v\u011bd\u011bli, kde m\u00e1 jeho vyu\u017eit\u00ed smysl,\u201c \u0159\u00edk\u00e1 profesor Shigeo Ohta z Japonska, celosv\u011btov\u011b pova\u017eovan\u00fd za otce a zakladatele v\u00fdzkumu molekul\u00e1rn\u00edho vod\u00edku a spoluzakladatel H2 Global Group.<\/p>\n\n\n\n

V\u00fdznamn\u00fdm miln\u00edkem je evropsk\u00fd patent EP3701956B1 s n\u00e1zvem \u201eProfylaktick\u00e9 nebo terapeutick\u00e9 \u010dinidlo pro demenci\u201c, jeho\u017e autorem je profesor Ohta a dr\u017eitelem H2 Global Group. Patent popisuje vyu\u017eit\u00ed molekul\u00e1rn\u00edho vod\u00edku v oblasti neurodegenerativn\u00edch onemocn\u011bn\u00ed v\u010detn\u011b demenc\u00ed a d\u00e1v\u00e1 \u010cesk\u00e9 republice na sv\u011btov\u00e9 sc\u00e9n\u011b unik\u00e1tn\u00ed postaven\u00ed.<\/p>\n\n\n\n

Klinick\u00e1 studie schv\u00e1len\u00e1 S\u00daKL: Kdy\u017e se spoj\u00ed v\u011bda, medic\u00edna a byznys<\/h3>\n\n\n\n

Na tento patent nyn\u00ed p\u0159\u00edmo navazuje prvn\u00ed klinick\u00e1 studie sv\u00e9ho druhu v \u010cR, schv\u00e1len\u00e1 S\u00daKL a Etickou komis\u00ed Fakultn\u00ed nemocnice Ostrava. Studie bude hodnotit bezpe\u010dnost inhalace molekul\u00e1rn\u00edho vod\u00edku u pacient\u016f s m\u00edrnou kognitivn\u00ed poruchou (MCI), za\u010dne v lednu 2026 a potrv\u00e1 \u0161est m\u011bs\u00edc\u016f. Z\u00fa\u010dastn\u00ed se j\u00ed p\u0159ibli\u017en\u011b 30 pacient\u016f ve v\u011bku 50\u201380 let, kte\u0159\u00ed budou inhalovat molekul\u00e1rn\u00ed vod\u00edk hodinu denn\u011b, p\u011bt dn\u00ed v t\u00fddnu po dobu t\u0159\u00ed m\u011bs\u00edc\u016f. N\u00e1sledn\u011b budou sledov\u00e1ni dal\u0161\u00ed t\u0159i m\u011bs\u00edce, v\u010detn\u011b kognitivn\u00edch test\u016f, vybran\u00fdch biochemick\u00fdch parametr\u016f a hodnocen\u00ed kvality \u017eivota.<\/p>\n\n\n\n

\u201eNechceme slibovat z\u00e1zraky, chceme z\u00edskat dal\u0161\u00ed data,\u201c shrnuje profesor \u0160koloud\u00edk. \u201eTeprve na jejich z\u00e1klad\u011b budeme moci zodpov\u011bdn\u011b \u0159\u00edci, jakou roli m\u016f\u017ee inhalace molekul\u00e1rn\u00edho vod\u00edku u t\u00e9to skupiny pacient\u016f hr\u00e1t.\u201c<\/p>\n\n\n\n

V\u00fdsledky budou po vyhodnocen\u00ed odborn\u011b publikov\u00e1ny a stanou se dal\u0161\u00edm krokem na cest\u011b k potenci\u00e1ln\u00edmu zrozen\u00ed prvn\u00edho registrovan\u00e9ho zdravotnick\u00e9ho prost\u0159edku s molekul\u00e1rn\u00edm vod\u00edkem na sv\u011bt\u011b pr\u00e1v\u011b v \u010cesk\u00e9 republice.<\/p>\n\n\n\n

V\u00fdzva k \u00fa\u010dasti ve studii: Pomoc sob\u011b, rodin\u011b i dal\u0161\u00edm generac\u00edm<\/h3>\n\n\n\n

Spole\u010dnost H2 Medical Technologies vyhla\u0161uje ve\u0159ejnou v\u00fdzvu pro dobrovoln\u00edky, kte\u0159\u00ed se cht\u011bj\u00ed studie z\u00fa\u010dastnit a spl\u0148uj\u00ed z\u00e1kladn\u00ed krit\u00e9ria: v\u011bk 50\u201380 let, celkov\u011b dobr\u00fd zdravotn\u00ed stav, diagn\u00f3za m\u00edrn\u00e9 kognitivn\u00ed poruchy nebo m\u00edrn\u00e9 a\u017e st\u0159edn\u011b t\u011b\u017ek\u00e9 demence a ide\u00e1ln\u011b bydli\u0161t\u011b v Ostrav\u011b a okol\u00ed, kde bude studie prob\u00edhat. \u00da\u010dast v t\u00e9to studii nezaru\u010duje \u017e\u00e1dn\u00fd zdravotn\u00ed benefit a nem\u011bla by b\u00fdt ch\u00e1p\u00e1na jako n\u00e1hrada standardn\u00ed l\u00e9\u010dby. Z\u00e1jemci se mohou hl\u00e1sit do 23. prosince 2025 na e-mail: david.skoloudik@H2medical.com<\/p>\n\n\n\n

H2 Global Group je zdravotnicko-technologick\u00e1 skupina, kter\u00e1 vyv\u00edj\u00ed, vyr\u00e1b\u00ed a exkluzivn\u011b dod\u00e1v\u00e1 inovativn\u00ed a bezpe\u010dn\u00e9 produkty a za\u0159\u00edzen\u00ed s molekul\u00e1rn\u00edm vod\u00edkem. Jej\u00ed \u0159e\u0161en\u00ed dnes vyu\u017e\u00edvaj\u00ed l\u00e1zn\u011b a wellness centra, sportovn\u00ed kluby a vrcholov\u00ed sportovci, soukrom\u00e9 kliniky, kosmetick\u00fd a beauty segment, firemn\u00ed zdravotn\u00ed programy a st\u00e1le \u010dast\u011bji i b\u011b\u017en\u00e9 dom\u00e1cnosti. Spolupracuje s l\u00e9ka\u0159i, terapeuty, univerzitami a v\u011bdeck\u00fdmi t\u00fdmy v \u010cR i zahrani\u010d\u00ed. Je dr\u017eitelem n\u011bkolika patent\u016f a u\u017eitn\u00fdch vzor\u016f a usiluje o registraci v\u016fbec prvn\u00edho zdravotnick\u00e9ho prost\u0159edku s molekul\u00e1rn\u00edm vod\u00edkem na sv\u011bt\u011b pr\u00e1v\u011b v \u010cesku s n\u00e1slednou expanz\u00ed do cel\u00e9ho sv\u011bta.<\/p>\n\n\n\n

\n

\u201eKdy\u017e je \u010dlov\u011bk zdrav\u00fd, m\u00e1 tis\u00edce probl\u00e9m\u016f, kter\u00e9 pot\u0159ebuje \u0159e\u0161it. Kdy\u017e onemocn\u00ed, z\u016fstane mu jedin\u00fd: jak se uzdravit,\u201c \u0159\u00edk\u00e1 David Mar\u0161\u00e1lek, zakladatel a CEO H2 Global Group, kter\u00fd p\u0159ed 14 lety p\u0159ivedl molekul\u00e1rn\u00ed vod\u00edk do \u010ceska a n\u00e1sledn\u011b do dal\u0161\u00edch evropsk\u00fdch zem\u00ed jako historicky prvn\u00ed dopln\u011bk stravy sv\u00e9ho druhu na sv\u011bt\u011b. Od t\u00e9 doby se molekul\u00e1rn\u00ed vod\u00edk d\u00edky dal\u0161\u00edmu v\u00fdzkumu, v\u00fdvoji a v\u00fdrob\u011b nov\u00fdch generac\u00ed produkt\u016f a p\u0159\u00edstroj\u016f dostal do \u010desk\u00fdch dom\u00e1cnost\u00ed, firem, l\u00e1zn\u00ed, klinik a dal\u0161\u00edch m\u00edst, kde lid\u00e9 hledaj\u00ed \u0161etrnou cestu k podpo\u0159e zdrav\u00ed, vitality a dlouhov\u011bkosti.<\/p>\n<\/blockquote>\n\n\n\n

\u201eI p\u0159es tis\u00edce publikovan\u00fdch studi\u00ed a odborn\u00fdch \u010dl\u00e1nk\u016f popisuj\u00edc\u00edch molekul\u00e1rn\u00ed vod\u00edk mus\u00edme b\u00fdt pokorn\u00ed. Je na\u0161\u00ed povinnost\u00ed rozli\u0161ovat, co je marketing a co je skute\u010dn\u00e1 medic\u00edna zalo\u017een\u00e1 na d\u016fkazech (EBM),\u201c zd\u016fraz\u0148uje PharmDr. Milan Kraj\u00ed\u010dek. \u201eProto investujeme do regulovan\u00e9ho v\u00fdzkumu, klinick\u00fdch studi\u00ed a spolupr\u00e1ce se \u0161pi\u010dkov\u00fdmi pracovi\u0161ti,\u201c dod\u00e1v\u00e1.<\/p>\n\n\n\n

H2 Global Group tak propojuje n\u011bkolik rovin spole\u010densk\u00e9 odpov\u011bdnosti: V\u011bdeckou (systematick\u00fd v\u00fdzkum a klinick\u00e9 testov\u00e1n\u00ed), Etickou (spolupr\u00e1ce se S\u00daKL a etick\u00fdmi komisemi, d\u016fraz na bezpe\u010dnost pacienta), Ekonomickou (rostouc\u00ed trh medic\u00ednsk\u00fdch technologi\u00ed a preventivn\u00ed medic\u00edny) a Lok\u00e1ln\u00ed (inovace vznikaj\u00ed v \u010cR, ale c\u00edl\u00ed na pacienty po cel\u00e9m sv\u011bt\u011b).<\/p>\n\n\n\n

Unik\u00e1tn\u00ed p\u0159\u00edle\u017eitost pro investory b\u00fdt u zrodu \u201emedic\u00edny vod\u00edkov\u00e9 \u00e9ry\u201c<\/h3>\n\n\n\n

Alzheimerova demence a dal\u0161\u00ed kognitivn\u00ed poruchy p\u0159edstavuj\u00ed jeden z nejv\u011bt\u0161\u00edch trh\u016f budoucnosti, a to nejen v medic\u00edn\u011b, ale i ve slu\u017eb\u00e1ch, technologi\u00edch a dlouhodob\u00e9 p\u00e9\u010di. Jak\u00e9koli \u0159e\u0161en\u00ed, kter\u00e9 dok\u00e1\u017ee zlep\u0161it kvalitu \u017eivota pacient\u016f, odd\u00e1lit ztr\u00e1tu sob\u011bsta\u010dnosti nebo sn\u00ed\u017eit z\u00e1t\u011b\u017e pe\u010dovatel\u016f, m\u00e1 obrovsk\u00fd spole\u010densk\u00fd a ekonomick\u00fd dopad.<\/p>\n\n\n\n

Tuto p\u0159\u00edle\u017eitost ji\u017e uchopila \u0159ada \u010desk\u00fdch investor\u016f, kte\u0159\u00ed se stali sou\u010d\u00e1st\u00ed H2 Global Group a pod\u00edlej\u00ed se na rozvoji \u201emedic\u00edny budoucnosti\u201c. Po covidov\u00e9 krizi roste celosv\u011btov\u00e1 popt\u00e1vka po inovativn\u00edch MedTech a HealthTech \u0159e\u0161en\u00edch, kter\u00e1 zefektiv\u0148uj\u00ed p\u00e9\u010di, podporuj\u00ed prevenci a c\u00edl\u00ed i na aktivn\u00ed dlouhov\u011bkost (active longevity) \u2013 aby lid\u00e9 \u017eili nejen d\u00e9le, ale i kvalitn\u011bji. Dal\u0161\u00ed investo\u0159i se mohou p\u0159ipojit pr\u00e1v\u011b v t\u00e9to rozhoduj\u00edc\u00ed f\u00e1zi, v okam\u017eiku, kdy se v jednom projektu potk\u00e1v\u00e1 patentov\u011b chr\u00e1n\u011bn\u00e9 know-how, regulovan\u00fd klinick\u00fd v\u00fdzkum, glob\u00e1ln\u011b rostouc\u00ed tr\u017en\u00ed popt\u00e1vka a \u010desk\u00e1 technologie se sv\u011btov\u00fdm potenci\u00e1lem \u2013 tedy p\u0159esn\u011b to, co investo\u0159i hledaj\u00ed nej\u010dast\u011bji.<\/p>\n\n\n\n

B\u00fdt u toho, kdy\u017e se p\u00ed\u0161e nov\u00fd \u010desk\u00fd medic\u00ednsk\u00fd p\u0159\u00edb\u011bh<\/h3>\n\n\n\n

Alzheimerova demence dramaticky m\u011bn\u00ed \u017eivoty pacient\u016f i jejich bl\u00edzk\u00fdch a odborn\u00edci varuj\u00ed, \u017ee bez aktivn\u00edho \u0159e\u0161en\u00ed p\u0159eroste v hlubok\u00fd spole\u010densk\u00fd a ekonomick\u00fd probl\u00e9m. Projekt H2 Medical Technologies a dlouhodob\u00e9 aktivity skupiny H2 Global Group ukazuj\u00ed, \u017ee i z relativn\u011b mal\u00e9 zem\u011b m\u016f\u017ee vzej\u00edt iniciativa, kter\u00e1 posouv\u00e1 sv\u011btovou medic\u00ednu o krok d\u00e1l a z\u00e1rove\u0148 stav\u00ed do centra podnik\u00e1n\u00ed spole\u010denskou odpov\u011bdnost.<\/p>\n\n\n\n

\u201eTe\u010f je doba, kdy se rozhoduje, kdo a jak u toho bude \u2013 jako investor, jako odborn\u00edk, jako pacient, jako rodinn\u00fd pe\u010dovatel a jako budouc\u00ed u\u017eivatel technologi\u00ed na b\u00e1zi molekul\u00e1rn\u00edho vod\u00edku,\u201c uzav\u00edr\u00e1 Mar\u0161\u00e1lek.<\/p>\n\n\n\n

Zdroj: https:\/\/www.ceskenoviny.cz\/pr\/zpravy\/alzheimerova-demence-prulomove-ceske-setrne-reseni-meni-problem-v-prilezitost-a-investori-u-toho-nechteji-chybet\/2753498<\/a><\/p>\n\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

Alzheimer’s dementia ranks among the greatest challenges, and not just for an aging society. It can strike any of us at any time\u2014directly, within the family, or in our close circle\u2014and at certain stages, the patient is no longer even aware of it. It brings a massive burden to families, the healthcare system, and the… Alzheimerova demence: Pr\u016flomov\u00e9 \u010desk\u00e9 \u0159e\u0161en\u00ed \u0161etrn\u00e9 k pacient\u016fm m\u011bn\u00ed probl\u00e9m v p\u0159\u00edle\u017eitost. A investo\u0159i u toho necht\u011bj\u00ed chyb\u011bt.<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":1061,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1057","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/comments?post=1057"}],"version-history":[{"count":3,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1057\/revisions"}],"predecessor-version":[{"id":1081,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1057\/revisions\/1081"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/media\/1061"}],"wp:attachment":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/media?parent=1057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/categories?post=1057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/tags?post=1057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}